Juan Segura-Aguilar

ResearcherID Loop profile Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2023
Publications (10 Years): 12

Top Venues

Antioxidants (Basel, Switzerland)

Cellular and molecular life sciences : CMLS

Neurotoxicity research

ACS chemical neuroscience

University of Chile

Stockholm University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Chile Sep 01 1998

Chile

Full Professor :: Molecular & Clinical Pharmacology, ICBM, Faculty of Medicine

Uppsala Universitet

Sweden

Associate Professor :: Department of Pharmaceutical Biochemistry

Education History

Stockholm University Sep 01 1983 - Dec 14 1989

Sweden

PHD :: Biochemistry

Publications

Sandro Huenchuguala, Juan Segura-Aguilar
On the Role of Iron in Idiopathic Parkinson's Disease. Biomedicines 11 (11) (2023)
Sandro Huenchuguala, Juan Segura-Aguilar
Why are neuromelanin-containing dopaminergic neurons lost in idiopathic Parkinson's disease? Cellular and molecular life sciences : CMLS 80 (10) (2023)
Juan Segura-Aguilar, Bengt Mannervik
A Preclinical Model for Parkinson's Disease Based on Transcriptional Gene Activation via KEAP1/NRF2 to Develop New Antioxidant Therapies. Antioxidants (Basel, Switzerland) 12 (3) (2023)
Juan Segura-Aguilar, Bengt Mannervik
A Preclinical Model for Parkinson's Disease Based on Transcriptional Gene Activation via KEAP1/NRF2 to Develop New Antioxidant Therapies. Antioxidants (Basel, Switzerland) 12 (3) (2023)
Juan Segura-Aguilar, Patricia Muñoz, Jose Inzunza, Mukesh K Varshney, Ivan Nalvarte, Bengt Mannervik
Neuroprotection against Aminochrome Neurotoxicity: Glutathione Transferase M2-2 and DT-Diaphorase. Antioxidants (Basel, Switzerland) 11 (2) (2022)
Raúl Valdes, Alicia Armijo, Patricia Muñoz, Kjell Hultenby, Andres Hagg, Jose Inzunza, Ivan Nalvarte, Mukesh K Varshney, Bengt Mannervik, Juan Segura-Aguilar
Cellular Trafficking of Glutathione Transferase M2-2 Between U373MG and SHSY-S7 Cells is Mediated by Exosomes. Neurotoxicity research 39 (2) (2021)
Juan Segura-Aguilar
Comment on: "Activating Autophagy as a Therapeutic Strategy for Parkinson's Disease". CNS drugs 32 (7) (2019)
Juan Segura-Aguilar
Can we conclude a potential therapeutic action for Parkinson's disease by using postmortem tissue and a preclinical model based on an exogenous neurotoxin? Cell death & disease 9 (7) (2018)
Juan Segura-Aguilar
Neurotoxins as Preclinical Models for Parkinson's Disease. Neurotoxicity research 34 (4) (2018)
Andrea Herrera, Patricia Muñoz, Harry W M Steinbusch, Juan Segura-Aguilar
Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease? ACS chemical neuroscience 8 (4) (2017)
Sandro Huenchuguala, Patricia Muñoz, Juan Segura-Aguilar
The Importance of Mitophagy in Maintaining Mitochondrial Function in U373MG Cells. Bafilomycin A1 Restores Aminochrome-Induced Mitochondrial Damage. ACS chemical neuroscience 8 (10) (2017)
Andrea Herrera, Patricia Muñoz, Irmgard Paris, Gabriela Díaz-Veliz, Sergio Mora, Jose Inzunza, Kjell Hultenby, Cesar Cardenas, Fabián Jaña, Rita Raisman-Vozari, Katia Gysling, Jorge Abarca, Harry W M Steinbusch, Juan Segura-Aguilar
Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson's disease. Cellular and molecular life sciences : CMLS 73 (18) (2016)

Juan Segura-Aguilar.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Juan Segura-Aguilar